Healing together: Results from a pilot trial of 3,4‐Methylenedioxymethamphetamine‐enhanced cognitive‐behavioral conjoint therapy for posttraumatic stress disorder

Study limitation reported by the research below: “MDMA remains a Schedule I controlled substance in the U.S. as of the publication date; this trial was conducted under research authorization and does not reflect standard clinical availability.”